5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder (NCT05452772)
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Four sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University (NYU). The proposed study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in session 1 and either 30 mg or 40 mg in session 2); or 2) oral niacin (150 mg in session 1 and either 150 mg or 200 mg in session 2), with sessions 1 week apart.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 21 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Johns Hopkins University School of Medicine — Baltimore, Maryland
- New York University — New York, New York
📞 Contact the Study Coordinator
Phone: (410) 550-0056
Email: mwj@jhu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Tobacco Use Disorder
- Nicotine Replacement Therapy Prescribing and Lung Cancer Screening in Hospitalized Patients — Charleston, South Carolina
- Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness — Durham, North Carolina
- Smoking Cessation Behavioral Treatment Study — Columbia, Missouri
- Beta-Adrenergic Modulation of Drug Cue Reactivity — Tulsa, Oklahoma
- An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction — Columbia, Missouri
Explore by condition: All Tobacco Use Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.